Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 12/20 | 0.52 |
| ▸ | FLT3 | P36888 | 5/20 | 0.52 |
| ▸ | BLK | P51451 | 3/20 | 0.52 |
| ▸ | BTK | Q06187 | 9/20 | 0.50 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ITK | Q08881 | 3/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3693031 | 1.00 | TGM2 (0.56) | TGM2EGFRFLT3BLKBTK | |
| SCHEMBL13169517 | 0.90 | EGFR (0.61) | EGFRBTKITK | |
| SCHEMBL13169424 | 0.90 | EGFR (0.60) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL13169540 | 0.89 | EGFR (0.56) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL13170067 | 0.89 | PLK4 (0.47) | EGFRBTKJAK3MEN1KMT2A | |
| SCHEMBL13170072 | 0.88 | TGM2 (0.53) | TGM2EGFRBTKJAK3ITK | |
| SCHEMBL13169406 | 0.88 | EGFR (0.58) | EGFRBTKJAK3ITK | |
| SCHEMBL3693264 | 0.87 | BTK (0.53) | EGFRFLT3BTKJAK3MEN1 | |
| SCHEMBL13170055 | 0.87 | PLK4 (0.54) | EGFRFLT3BLKJAK3ITK | |
| SCHEMBL13170050 | 0.87 | PLK4 (0.61) | TGM2EGFRFLT3BLKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040549-B2 | Thiopyrimidine-based compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040549-B2 | Thiopyrimidine-based compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8846704-B2 | Thiopyrimidine-based compounds and uses thereof | YM Biosciences Austraila Pty Ltd (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846704-B2 | Thiopyrimidine-based compounds and uses thereof | YM Biosciences Austraila Pty Ltd (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140051703-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-20 | — | — | US | disclosed |
| US-20140051703-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-20 | — | — | US | disclosed |
| US-20140045848-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-13 | — | — | US | disclosed |
| US-20140045848-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-13 | — | — | US | disclosed |
| US-20100239631-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY LTD | 2010-09-23 | — | — | US | disclosed |
| US-20100239631-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY LTD | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045848-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | TGM2 965/4885EGFR 1570/4885FLT3 107/4885 |
| US-20100239631-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | TGM2 965/4885EGFR 1570/4885FLT3 107/4885 |
| US-20140051703-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | TGM2 965/4885EGFR 1570/4885FLT3 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.